Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Changes In Stockholders' Equity (Deficiency) (Unaudited)

v3.21.1
Condensed Statements of Changes In Stockholders' Equity (Deficiency) (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2019 $ 7 $ 57,177,858 $ (56,187,925) $ 989,940
Balance, shares at Dec. 31, 2019 717,274      
Common stock issued private placement offering [1] $ 1 24,304 24,305
Common stock issued private placement offering, shares [1] 52,000      
Shared-Based Compensation 116,820 116,820
Warrants granted to consultants 14,070 14,070
Net loss (1,159,758) (1,159,758)
Balance at Mar. 31, 2020 $ 8 57,333,052 (57,347,683) (14,623)
Balance, shares at Mar. 31, 2020 769,274      
Balance at Dec. 31, 2020 $ 25 72,421,242 (65,323,411) 7,097,856
Balance, shares at Dec. 31, 2020 2,541,529      
Shared-Based Compensation 106,850 106,850
Common stock issued in public offerings [2] $ 59 38,127,717 38,127,776
Common stock issued in public offerings, shares [2] 5,914,284      
Common stock issued for exercise of warrants $ 1 239,999 240,000
Common stock issued for exercise of warrants, shares 52,077      
Fair Value of Warrants Issued 211,976 211,976
Net loss (2,772,886) (2,772,886)
Balance at Mar. 31, 2021 $ 85 $ 111,107,784 $ (68,096,297) $ 43,011,572
Balance, shares at Mar. 31, 2021 8,507,890      
[1] net of offering costs of $80,000.
[2] net of offering costs of $3,270,000.